These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

365 related items for PubMed ID: 1681816

  • 1. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population.
    Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K, Meyer UA.
    DNA Cell Biol; 1991 Oct; 10(8):545-58. PubMed ID: 1681816
    [Abstract] [Full Text] [Related]

  • 2. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
    Evans WE, Relling MV.
    Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
    [Abstract] [Full Text] [Related]

  • 3. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.
    Broly F, Meyer UA.
    Pharmacogenetics; 1993 Jun; 3(3):123-30. PubMed ID: 8101460
    [Abstract] [Full Text] [Related]

  • 4. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.
    Griese EU, Asante-Poku S, Ofori-Adjei D, Mikus G, Eichelbaum M.
    Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134
    [Abstract] [Full Text] [Related]

  • 5. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population.
    Dahl ML, Johansson I, Palmertz MP, Ingelman-Sundberg M, Sjöqvist F.
    Clin Pharmacol Ther; 1992 Jan; 51(1):12-7. PubMed ID: 1346258
    [Abstract] [Full Text] [Related]

  • 6. CYP2D6 genotype determination in the Danish population.
    Brøsen K, Nielsen PN, Brusgaard K, Gram LF, Skjødt K.
    Eur J Clin Pharmacol; 1994 Jan; 47(3):221-5. PubMed ID: 7867674
    [Abstract] [Full Text] [Related]

  • 7. Debrisoquine polymorphism: novel CYP2D6 gene Bam HI restriction fragment length polymorphism in the Ngawbé Guaymí Indian of Panama.
    Petersen DD, Kong AN, Jorge LF, Nebert DW, Arias TD.
    Pharmacogenetics; 1991 Dec; 1(3):136-42. PubMed ID: 1688244
    [Abstract] [Full Text] [Related]

  • 8. Imipramine metabolism in relation to the sparteine oxidation polymorphism--a family study.
    Madsen H, Hansen TS, Brøsen K.
    Pharmacogenetics; 1996 Dec; 6(6):513-9. PubMed ID: 9014200
    [Abstract] [Full Text] [Related]

  • 9. Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs.
    Skoda RC, Gonzalez FJ, Demierre A, Meyer UA.
    Proc Natl Acad Sci U S A; 1988 Jul; 85(14):5240-3. PubMed ID: 2899325
    [Abstract] [Full Text] [Related]

  • 10. PCR-based CYP2D6 genotyping for Finnish lung cancer patients.
    Hirvonen A, Husgafvel-Pursiainen K, Anttila S, Karjalainen A, Pelkonen O, Vainio H.
    Pharmacogenetics; 1993 Feb; 3(1):19-27. PubMed ID: 8097947
    [Abstract] [Full Text] [Related]

  • 11. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism.
    Gaedigk A, Blum M, Gaedigk R, Eichelbaum M, Meyer UA.
    Am J Hum Genet; 1991 May; 48(5):943-50. PubMed ID: 1673290
    [Abstract] [Full Text] [Related]

  • 12. An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis.
    Broly F, Marez D, Sabbagh N, Legrand M, Millecamps S, Lo Guidice JM, Boone P, Meyer UA.
    Pharmacogenetics; 1995 Dec; 5(6):373-84. PubMed ID: 8747409
    [Abstract] [Full Text] [Related]

  • 13. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes.
    Kagimoto M, Heim M, Kagimoto K, Zeugin T, Meyer UA.
    J Biol Chem; 1990 Oct 05; 265(28):17209-14. PubMed ID: 2211621
    [Abstract] [Full Text] [Related]

  • 14. Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes.
    Daly AK, Armstrong M, Monkman SC, Idle ME, Idle JR.
    Pharmacogenetics; 1991 Oct 05; 1(1):33-41. PubMed ID: 1688241
    [Abstract] [Full Text] [Related]

  • 15. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology.
    Steen VM, Andreassen OA, Daly AK, Tefre T, Børresen AL, Idle JR, Gulbrandsen AK.
    Pharmacogenetics; 1995 Aug 05; 5(4):215-23. PubMed ID: 8528268
    [Abstract] [Full Text] [Related]

  • 16. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis.
    Dahl ML, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjöqvist F.
    J Pharmacol Exp Ther; 1995 Jul 05; 274(1):516-20. PubMed ID: 7616439
    [Abstract] [Full Text] [Related]

  • 17. Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6.
    Wang SL, Huang JD, Lai MD, Liu BH, Lai ML.
    Clin Pharmacol Ther; 1993 Apr 05; 53(4):410-8. PubMed ID: 8097442
    [Abstract] [Full Text] [Related]

  • 18. Prediction of phenotype for acetylation and for debrisoquine hydroxylation by DNA-tests in healthy human volunteers.
    Graf T, Broly F, Hoffmann F, Probst M, Meyer UA, Howald H.
    Eur J Clin Pharmacol; 1992 Apr 05; 43(4):399-403. PubMed ID: 1451720
    [Abstract] [Full Text] [Related]

  • 19. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles.
    Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M.
    J Pharmacol Exp Ther; 1996 Jul 05; 278(1):441-6. PubMed ID: 8764380
    [Abstract] [Full Text] [Related]

  • 20. Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population study.
    Madsen H, Nielsen KK, Brøsen K.
    Br J Clin Pharmacol; 1995 Apr 05; 39(4):433-9. PubMed ID: 7640151
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.